This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Three recently published studies provide preclinical proof-of-concept that bispecific antibodies can be deployed against mutations in two of cancer's most notorious genes, TP53 and RAS. The strategy could also prove effective against T-cell malignancies, which lack good treatment options compared with B-cell blood cancers.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on March 25, 2021
doi: 10.1158/2159-8290.CD-ND2021-0105
Expanding the Reach of Bispecifics
Jump to section
Advertisement